GILD has clearly gained HCV market share in the US market. GILD attributes this to the success of the authorized generics for Harvoni and Epclusa. ABBV said on today's CC that it has encountered more competition in the managed-Medicaid segment of the US market.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.